Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹123 Cr
verified against source
Revenue YoY
-0.6%
reported change
EBITDA
₹78 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Vidhi Specialty Food Ingredients reported FY26 revenue of ₹380 crore, marginally down from ₹382.3 crore due to global demand slowdown and tariff volatility. However, EBITDA grew 14.7% to ₹78 crore and PAT rose 20.8% to ₹49.15 crore, driven by product mix improvement and cost controls. EBITDA margin expanded 261 bps to 20.52%, with manufacturing sales margins at ~24-25%. Management guided for full capacity utilization in FY27 and expects value-added product contribution to double from 5% to 10-12%. A major capex of ₹75-85 crore is planned for new high-margin product lines, with commissioning in H2 FY28. The pharma coating range (Quote Icon) is in advanced sampling stages. Key risk: continued geopolitical disruptions in key export markets (Iran, Bangladesh, Philippines) could delay demand recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects full utilization of both Dhar and RoA facilities in FY27, driven by robust demand recovery.
- Contribution of high-margin value-added products expected to rise from 5% to 10-12% in FY27, with potential for higher if approvals come through.
- Investment in new high-margin product line at Dhar, with commissioning expected in 18 months (H2 FY28). First phase revenue target of ₹125-150 crore.
- Aggressive sampling with pharma companies; approval cycle ~6 months; initial feedback favorable.
Risks flagged
- Markets like Iran, Bangladesh, and Philippines are severely impacted by geopolitical tensions, delaying demand recovery.
- Analyst raised concern about US tariff impact; management acknowledged volatility but noted US market has stabilized. However, further tariff changes could affect sales.
- Interest cost increased due to withdrawal of export finance subvention by Indian government in December 2025, impacting finance costs.
- Large capex of ₹75-85 crore for new product line may face delays or cost overruns; commissioning timeline of 18 months is ambitious.
Key quotes
- The manufacturing sales has been 330 crores from which most of this EBITDA margin has evolved. So if you see the actual EBITDA margin on manufactured sales it would be close to 24-25%.
- The US was never planning to ban synthetic food colors. So that perception is completely false.
- We have a existing business plan on which we are working commercializing these products which can be done every 18-24 months. We have a new pipeline of products that are being commercialized which leaves us with a very clear pathway of growth for a longer period of time, one whole decade from now.
Research modules